OmniAb, Inc..
OABI.US | Research and experimental development on natural sciences and engineering
OmniAb, Inc. is a biopharmaceutical company that discovers and develops human therapeutic antibodies. The company offers its OmniAb discovery platform, which includes transgenic animals for antibody discovery, and also provides services such as antibody engineering, humanization, and developability ...Show More
Better Health for All
20
OmniAb's principal goods and services, including its xPloration platform and Fc-silencing technology (STR), are entirely devoted to enabling the discovery and development of therapeutic antibodies. The STR technology specifically aims to reduce potential toxicity and improve the safety and efficacy of these antibodies, which represents an exceptional health benefit.
1
The xPloration platform enables rapid and high-throughput antibody discovery.
2
This aligns with 95-97% of the portfolio delivering exceptional health benefits, with the entire business devoted to health improvement.
Fair Money & Economic Opportunity
0
OmniAb, Inc. is a biopharmaceutical company focused on antibody discovery and development, licensing its platform and providing related services to other companies in the drug development space.
1
The company does not offer lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its core business model, resulting in a score of 0 for each.
Fair Pay & Worker Respect
40
OmniAb demonstrates strong worker engagement, with employee reviews indicating an overall company rating of 4.7 out of 5 and a culture and values rating of 4.7 out of 5, which translates to approximately 94% engagement.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess OmniAb, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
OmniAb, Inc. has a formal whistleblower protection policy that includes an anonymous ethics hotline, which is monitored by the Audit Committee.
1
The company's board of directors consists of seven members, with five identified as independent, resulting in approximately 71.4% independent directors.
2
OmniAb, Inc. also has an anti-corruption policy, adopted in 2008 and revised multiple times, which outlines procedures to prevent violations of anti-corruption laws, including the FCPA and UK Bribery Act.
3
This policy details prohibited practices, mandates due diligence on third-party agents, and requires anti-bribery provisions in international contracts.
4
However, the policy document does not provide quantitative data on training frequency or effectiveness metrics.
5
Kind to Animals
0
No evidence available to assess OmniAb, Inc. on Kind to Animals.
No War, No Weapons
0
No specific, concrete data points were found in the provided articles to assess OmniAb, Inc. against the 'No War, No Weapons' ethical value. The articles primarily describe the company's focus on therapeutic antibody discovery and antigen design.
1
While one article mentions a license agreement between OmniAb, Inc. and Tharimmune, Inc. for a prophylactic treatment that could be used by military personnel, it does not provide any quantitative data on OmniAb's revenue from this agreement, nor does it indicate that OmniAb's core platform or R&D is considered dual-use or directly involved in military contracts or arms manufacturing.
2
Information regarding military contracts and programs in other articles is not attributed to OmniAb, Inc.
Planet-Friendly Business
0
No evidence available to assess OmniAb, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding OmniAb, Inc.'s (OABI.US) performance on any of the KPIs related to Respect for Cultures & Communities. The articles either discuss general concepts such as Free, Prior, and Informed Consent (FPIC) or focus on other aspects of the company's operations, such as antibody discovery services, environmental management policy, or carbon footprint. There is no information on partnerships with community groups, revenue reinvested locally, cultural appropriation incidents, cultural impact assessments, local employment, grievance mechanisms, FPIC participation rates, community governance, cultural preservation investments, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
Safe & Smart Tech
0
The provided privacy policy from OmniAb.com is very general and explicitly states a lack of specific details necessary to assess any of the Safe & Smart Tech metrics.
1
No quantitative data, regulatory actions, violations, fines, certifications, awards, or comparisons to industry benchmarks are mentioned.
2
Consequently, there is no evidence to score any of the KPIs for data protection, cybersecurity, or responsible AI.
Zero Waste & Sustainable Products
-50
OmniAb implemented a waste reduction initiative by partnering with Polycarbin for a lab plastic recycling program, which diverted 4552 lbs of lab plastic.
1
The company conducts annual waste audits for major facilities, as implied by monthly reporting from the Polycarbin partnership for lab plastics. No waste disposal violations, fines, or regulatory actions are mentioned in the provided articles for the past three years.
2
OmniAb provides clear disposal information on all products and packaging, and uses an internal platform (OASIS) to educate employees on sustainability.
3